Sanofi (SNY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $47.64. It has a SharesGrow Score of 75/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SNY = $222.77 (+367.6% from the current price, the stock appears undervalued). Analyst consensus target is SNY = $57 (+19.7% upside).
Valuation: SNY trades at a trailing Price-to-Earnings (P/E) of 9.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.41.
Financials: revenue is $46.7B, +1%/yr average growth. Net income is $7.8B, growing at +2.7%/yr. Net profit margin is 16.7% (healthy). Gross margin is 72.3% (+2.5 pp trend).
Balance sheet: total debt is $21.8B against $71.4B equity (Debt-to-Equity (D/E) ratio 0.31, conservative). Current ratio is 1.09 (adequate). Debt-to-assets is 17.2%. Total assets: $126.8B.
Analyst outlook: 14 / 27 analysts rate SNY as buy (52%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 79/100 (Pass), Growth 45/100 (Partial), Past 100/100 (Pass), Health 83/100 (Pass), Moat 90/100 (Pass), Future 58/100 (Partial), Income 70/100 (Pass).
